Study guide

12.1 Non-Invasive Ventilation in Cardiac Patients

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

12.1 Non-Invasive Ventilation in Cardiac Patients

Key Takeaways Explain This Topic AI

CPAP delivers one continuous pressure (typically 5-12 cmH2O) that recruits alveoli and offloads inspiratory work; bilevel adds an inspiratory pressure above the expiratory pressure, and that IPAP-EPAP gap is what augments tidal volume and clears CO2.

Positive intrathoracic pressure is a hemodynamic drug: it lowers venous return and preload and lowers LV transmural pressure and therefore afterload, which is why NIV is first-line in acute cardiogenic pulmonary edema and reduces intubation rates.

The same physiology is harmful in the preload-dependent patient: in RV infarction, RV failure or hypovolemia, positive pressure drops cardiac output and raises RV afterload, so hypotension after starting NIV means lower the pressure and give volume, not raise the pressure.

Typical starting settings are CPAP 5-8 cmH2O titrated to 10-12, or bilevel 10-12/5 cmH2O titrated in 2 cmH2O steps toward 6-8 mL/kg predicted body weight; reassess pH, PaCO2, respiratory rate and oxygenation within 1-2 hours.

Failure to improve pH, respiratory rate, or oxygenation after a 1-2 hour trial, or any decline in mental status, means intubate rather than continue NIV - delayed intubation is the classic NIV harm.

Last updated: August 2026

Why NIV Is a Cardiac Therapy, Not Just a Respiratory One

In acute cardiogenic pulmonary edema (ACPE) the failing left ventricle raises left atrial and pulmonary capillary hydrostatic pressure, alveoli and interstitium flood, intrapulmonary shunt rises, lung compliance falls, and the patient recruits accessory muscles. The work of breathing in florid flash pulmonary edema can consume 20-25% of total cardiac output and generates large negative intrathoracic swings that further increase venous return into an already congested circuit and increase left ventricular (LV) wall stress. Non-invasive ventilation (NIV) interrupts that cycle at several points at once, which is why applying a mask can transform a patient's appearance within 15-20 minutes without a single milligram of new drug reaching them.

CPAP Versus Bilevel: The Distinction CMC Tests

Continuous positive airway pressure (CPAP) delivers one constant pressure across the entire respiratory cycle. It does not deliver a breath and does not augment tidal volume. It splints open flooded and collapsed alveoli, raises functional residual capacity (FRC), reduces intrapulmonary shunt, and counterbalances intrinsic PEEP so the inspiratory muscles do less work. It fixes oxygenation.

Bilevel positive airway pressure (bilevel NIV, commercially BiPAP) delivers an inspiratory positive airway pressure (IPAP) and a lower expiratory positive airway pressure (EPAP) . The difference between the two is the delivered pressure support , and that gap is what augments tidal volume and therefore minute ventilation. This yields the single most useful titration rule on the exam: an oxygenation problem is treated by raising EPAP and FiO2; a CO2 or pH problem is treated by widening the IPAP-EPAP gap (raising IPAP). Raising IPAP and EPAP together by the same amount improves oxygenation but does nothing for ventilation, because the supporting pressure difference is unchanged.

The Hemodynamic Effects

Mechanism Physiologic result Consequence in the cardiac patient

Raised intrathoracic pressure compresses the vena cavae and right atrium Venous return and RV preload fall Relieves congestion in the volume-overloaded LV failure patient; causes hypotension in the hypovolemic or RV-dependent patient

LV transmural pressure = LV systolic pressure minus intrathoracic pressure Positive intrathoracic pressure reduces LV transmural pressure True afterload reduction - stroke volume rises in the failing, afterload-sensitive LV

Alveolar recruitment and reduced shunt PaO2 rises, hypoxic pulmonary vasoconstriction eases Lower pulmonary vascular resistance, less RV strain, better myocardial oxygen supply

Reduced work of breathing Respiratory muscle oxygen consumption falls Lower total myocardial oxygen demand, less catecholamine surge, less ischemia

Lung overdistension at high pressure Alveolar vessels compressed, pulmonary vascular resistance rises Worsens RV afterload in RV failure, pulmonary hypertension, RV infarction

The flip side matters as much as the benefit. A patient with RV infarction, acute RV failure, pulmonary hypertension, tamponade physiology or frank hypovolemia is preload-dependent . In that patient the same positive pressure that unloads a failing LV removes the venous return the RV needs and simultaneously raises RV afterload. Cardiac output falls, sometimes abruptly. When blood pressure drops after NIV is applied, the correct response is to reduce the expiratory pressure, give volume, and reassess - not to escalate pressure because the saturation is still low.

Indications and Contraindications

Strongest indications: acute cardiogenic pulmonary edema (bilevel or CPAP, both supported by the 2017 ERS/ATS NIV guideline and by meta-analyses showing reduced intubation rates); COPD exacerbation with hypercapnic acidosis (pH below 7.35 with PaCO2 above 45 mmHg - the highest-quality NIV indication of all); selected hypoxemic respiratory failure; post-extubation support and post-extubation respiratory failure in high-risk patients; obesity hypoventilation and obstructive sleep apnea; palliative relief of dyspnea in the do-not-intubate patient.

Contraindications: cardiac or respiratory arrest; inability to protect the airway or clear secretions; depressed or agitated mental status that prevents cooperation; facial trauma, burns, or recent upper airway or upper GI surgery; active vomiting or upper gastrointestinal bleeding; undrained pneumothorax; bowel obstruction; and hemodynamic instability or life-threatening arrhythmia that demands immediate intubation and full support.